Curis, Inc. (CRIS)
After hours:
| Previous Close | 14.71 |
| Open | 14.56 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 14.56 - 15.35 |
| 52 Week Range | 0.38 - 17.49 |
| Volume | |
| Avg. Volume | 31,672 |
| Market Cap | 90.474M |
| Beta (5Y Monthly) | 3.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.96 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.75 |
PR NewswireCuris to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.
ZacksStrength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares of Curis common stock to a new employee, with a grant date of April 1, 2024 (the "Q2 2024 Inducement Grant").
